Cite
HARVARD Citation
Zhang, Y. et al. (2022). BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia. Blood science. 4 (4), pp. 199-204. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zhang, Y. et al. (2022). BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia. Blood science. 4 (4), pp. 199-204. [Online].